• Successful completion of Phase Ib MAD clinical trial with daily dosage up to 320 mg confirming the excellent safety and tolerability profile of PRI-002
  • Closure of first seed investment by private equity firm Riesner Verwaltungs GmbH
  • Acquisition of the PRI-002, PRI-003 and PRI-004 IP portfolio from Forschungszentrum Jülich
  • Successful completion of the first-in-human phase I SAD clinical trial for PRI-002
  • Start of the Phase I MAD clinical trial for PRI-002 in December 2018
  • Founding of Priavoid
  • Initiation of series A financing
  • Basic Research at Forschungszentrum Jülich
  • Research funding by Forschungszentrum Jülich | Helmholtz Gesellschaft | VW Stiftung | Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf